Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

322.70 +10.29 (+3.29%)
Streaming Delayed Price Updated: 1:39 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Krystal Biotech Inc. (NASDAQ: KRYS) is a Leading Gainer in 2/26 Morning Trading
Via Investor Brand Network
News headline image
Earnings Scheduled For February 26, 2024 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
News headline image
A Preview Of Krystal Biotech's Earnings ↗
 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
This Stock Has Quadrupled in 5 Years. Can It Do It Again? ↗
Have investors already missed the boat with this stock? 
Via The Motley Fool
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
A Preview Of Krystal Biotech's Earnings ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Krystal Biotech ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Krystal Biotech ↗
 
Via Benzinga
News headline image
Analyst Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
 
Via Benzinga
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
News headline image
What Will AbbVie Buy Next? ↗
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
News headline image
Up 48% in 2023, Is This Biotech Stock a Buy? ↗
How much longer can this biotech's run last? 
Via The Motley Fool
News headline image
Why Shares of Krystal Biotech Are Rising Monday ↗
The company is moving quickly to market its newly approved therapy. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 ↗
 
Via Benzinga
News headline image
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M ↗
Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
News headline image
3 Biotech Stocks to Buy Before the Breakout ↗
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023 ↗
 
Via Benzinga
News headline image
2 Soaring Stocks With More Upside Potential ↗
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
News headline image
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
News headline image
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem. 
Via MarketBeat
News headline image
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
News headline image
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment ↗
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.